Current Report · Items 1.01, 9.01 · 8-K
RAPHAEL PHARMACEUTICAL INC
RAPHOTCEQUITYCurrent
Entry into a Material Definitive Agreement
Item 1.01 Entry into a Material Definitive Agreement. On July 30, 2026, Raphael Pharmaceutical Inc. (the “Company”) entered into an Enterprise AI Transformation and Growth Partnership with AIcreatesAI Inc. (“AIcreatesAI”) pursuant to an Annual Managed Services Proposal and Agreement (the “Agreement”). The Agreement became effective on July 30, 2026, the date of the last signature by the parties.…
Recent company filings
- 10-Q filingAug 14, 2026
- Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory ArrangementsJul 17, 2026
- 10-Q filingMay 14, 2026
- 10-K filingMar 31, 2026
- Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory ArrangementsMar 24, 2026
Disclosure sections
Item 1.01Item 1.01 - Entry into Material Agreement
Item 1.01 Entry into a Material Definitive Agreement.
On July 30, 2026, Raphael Pharmaceutical Inc. (the “Company”)
entered into an Enterprise AI Transformation and Growth Partnership with AIcreatesAI Inc. (“AIcreatesAI”) pursuant to an Annual
Managed Services Proposal and Agreement (the “Agreement”). The Agreement became effective on July 30, 2026, the date of the
last signature by the parties.
Under the Agreement, AIcreatesAI will serve as the Company’s managed
artificial intelligence transformation, commercialization, communications, product and growth operations partner. The initial term is
twelve months. The annual managed-services fee is $180,000, payable in monthly installments of $15,000, subject to the deferred-payment
provisions described in the Agreement.
The services contemplated by the Agreement include, among other matters,
digital transformation and operating-system implementation; website, application and CRM development and management; analytics and executive
dashboards; approved marketing, content, social-media, email and press support; research and product intelligence; partnership-development
support; and investor and corporate communications, in each case subject to the Company’s approval, applicable law and the compliance
controls set forth in the Agreement.
The Agreement provides that when funds are temporarily unavailable, any unpaid service invoices automatically become deferred payment
obligations and remain payable upon the Company’s receipt of financing, capital investment, commercial revenues or other available financial
resources. With AIcreatesAI’s written consent, the Company may satisfy deferred payment obligations through the issuance of Company common
shares, subject to applicable securities laws and OTC Markets requirements.
The Agreement also contemplates the design, development and maintenance
of a Company-branded digital token platform, subject to Board approval and applicable law. In consideration for ongoing operation and
maintenance of that platform, AIcreatesAI is entitled to receive two percent (2%) of the net profits generated from the platform, separate
from the annual service fee. The Agreement does not itself authorize regulated token issuance, exchange listing, custody, securities sales
or other regulated financial services.
The Agreement may be terminated by either party for a material breach
that remains uncured for fifteen days after written notice. The parties are independent contractors, and the Agreement does not create
a partnership, joint venture, fiduciary relationship or equity partnership.
The foregoing description of the Agreement does not purport to be complete
and is qualified in its entirety by reference to the Agreement, which is filed as Exhibit 10.1 to this Current Report on Form 8-K and
is incorporated herein by reference.